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In the yeast Saccharomyces cerevisiae, yeast RAS proteins are potent activators of adenylate cyclase. In the
present work we measured the activity of adenylate cyclase in membranes from Saccharomyces cerevisiae which
overexpress this enzyme. The response of the enzyme to added RAS2 proteins bound with various guanine
nucleotides and their analogs suggests that RAS2 proteins are active in their GTP-bound form and are virtually
inactive in their GDP-bound form. Also, active RAS2 protein is not inhibited by inactive RAS2, suggesting that
the inactive form does not compete with the active form in binding to its effector.
ras genes are ubiquitous in eucaryotes (9, 24, 27, 32). In
mammals, they comprise a family of at least three members
(H-, K-, and N-ras) which share structural and functional
properties. They were first identified, in their mutant forms,
as potent oncogenes (4, 5, 7, 12, 22, 26, 29, 33, 36, 38, 39).
Although the normal ras genes are not oncogenic, they too
can cause the malignant transformation of cells when ex-
pressed at abnormally high levels (7). In mammals, Ras
proteins are 21,000-dalton molecules that are localized to the
cytoplasmic side of the cell membrane (44). They bind GTP
and GDP (30) and have an intrinsic GTPase activity (14, 21,
35). Moreover, some oncogenic forms of Ras protein are
deficient in GTPase activity (14, 21, 35). Based on these
properties, and reasoning by analogy to other known gua-
nine nucleotide-binding proteins, the G proteins (reviewed in
reference 15), most investigators think that Ras proteins act
as transducers to convey extracellular signals to an intracel-
lular effector pathway. According to this model, Ras protein
bound to GTP activates its effector, and then shuts itself off
through its intrinsic GTPase activity. Mutant Ras proteins
which are defective in GTPase would thus cause abnormally
prolonged stimulation of the effector system, explaining their
oncogenicity.
The RAS1 and RAS2 proteins of the yeast Saccharomyces
cerevisiae provide an ideal system for testing aspects of this
model. They are structurally, biochemically, and function-
ally similar to the mammalian Ras proteins, and at least one
of their effector systems is known (3, 9, 10, 18, 24, 37, 41,
42). The yeast RAS genes were originally isolated by using
mammalian ras genes as probes to screen libraries of S.
cerevisiae genomic DNA. They encode proteins which are
highly homologous to the mammalian Ras proteins, particu-
larly at their amino termini (9, 24). They undergo processing
events very similar to those of their mammalian counterparts
and localize to membrane fractions (8, 13, 25, 31, 44). Like
the mammalian proteins, they bind guanine nucleotides; they
have an intrinsic GTPase activity, and this activity is re-
duced in the mutant RAS2val-19 protein which has an amino
acid substitution analogous to one of the oncogenic forms of
the mammalian Ras proteins (37, 41; unpublished observa-
tions). RAS1 and RAS2 proteins are activators of yeast
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adenylate cyclase, and this appears to be their major phys-
iological effector (3, 42).
We have previously shown that yeast and mammalian Ras
proteins purified from Escherichia colilvector expression
systems are potent activators of the adenylate cyclase pres-
ent in crude fractions of yeast membranes (3). Surprisingly,
we observed that RAS2 protein bound to GDP appeared to
activate adenylate cyclase although activation was only one
half to one third that of RAS2 protein bound to a
nonhydrolyzable GTP analog. We have since cloned the
yeast gene encoding adenylate cyclase (17), and that has
enabled us to create yeast strains which greatly overexpress
that enzyme. As a result, we have been able to develop a
more sensitive biochemical assay for Ras proteins. Using
this system we have reexamined the guanine nucleotide
dependence of RAS2 protein and conclude that RAS2 may
be active only in its GTP-bound form. Moreover, we have
found that RAS2 bound with a GDP analog does not compete
with RAS2 bound with a GTP analog for activating its
effector. This finding has relevance for understanding how
overexpression of a normal Ras protein can be oncogenic.
MATERIALS AND METHODS
Construction of plasmid pADH-CYRJ. The entire coding
sequence of the CYR] gene was isolated from pCYRI-2(SalI)
(17) by complete digestion with Sall and partial digestion
with Clal. The 8.1-kilobase fragment was cloned into YRp7,
which was digested with Sall and ClaI to produce YRp7-
CYR] as shown in Fig. 1. YRp7 contains the TRPI marker
and ARSl for replication as a multicopy plasmid in S.
cerevisiae (34). Then YRp7-CYRJ was cleaved with SalI and
ligated with a 400-base-pair SphI-HindIII fragment contain-
ing the yeast alcohol dehydrogenase promoter (1) after their
cohesive ends were filled in or removed by treatment with
Klenow fragment of E. coli DNA polymerase I. The SphI-
HindIII fragment had been isolated from pLD94 obtained
from L. Davidow and M. Gollahera of Pfizer Central Re-
search (Groton, Conn.). The direction of the ADHI pro-
moter inserted was confirmed by the reconstruction of a SalI
cleavage site at the junction of the filled-in Sall and SphI
sites.
Growth of S. cerevisiae and construction of strain TK-Blll.
S. cerevisiae was grown in YPD (1% yeast extract, 2%
peptone, and 2% glucose) or, to maintain selective pressure
for plasmids, in synthetic medium (0.67 g of yeast nitrogen
base per liter, 2% glucose, and appropriate auxotrophic
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ACTIVATION OF YEAST RAS PROTEINS 2129
supplements). General genetic manipulations of S. cerevi-
siae were performed as described by Mortimer and Haw-
thorne (23). Yeast transformations were performed as de-
scribed (16). The strain TK-B111 (MATTa rasl::HIS3
ras2::URA3 trpl Ieu2 ade8 cani pADH-CYRJ) was con-
structed by transforming the plasmid pADH-CYRI into
strain SPK1 (MATTa rasl::HIS3 ras2::URA3 trpl leu2 ade8
cani pTLC-RAS2), followed by screening for segregants
that lost the RAS2-bearing plasmid but retained pADH-
CYR]. The plasmid pTLC-RAS2 contains the yeast RAS2
gene cloned into a plasmid that confers sensitivity to
canavanine. Details of this construction will be described
elsewhere.
Preparation of yeast extracts and purification of RAS2. The
preparation of yeast membrane extracts has been previously
described (3, 42). RAS2 and RAS2va1-L9 were purified from
E. coli isolates containing expression systems as previously
described (3). These E. coli strains express complete RAS2
proteins using the lambda PL promoter.
Assays. Adenylate cyclase assays were performed as de-
scribed (3, 28, 42) except that an ATP-generating system was
omitted. The legend to Fig. 3 describes a typical assay in
more detail. All assays were carried out with 10 pug of yeast
extracts. Divalent cations, RAS2, and guanine nucleotides
were varied as indicated in the figure legends. Incubations
were for 30 min at 30°C. The data are expressed as units of
adenylate cyclase, where 1 unit catalyzed the formation of
1.0 pmol of cyclic AMP per min per mg of yeast membrane
protein. Similar results were obtained with at least two
preparations each of RAS2, RAS2va,-I9, and yeast membrane
extracts. The experiments reported here were carried out
I I
\C- . v
FIG. 2. Coomassieblue-stainedsodiumdodecylsulfate-polyacryl-
amide gel of purified S. cerevisiae RAS2 proteins. Lane 1. Wild-type
RAS2, 5.6 ,ug; lane 2. RAS2va 19, 12.6 ,ug; lane 3, markers.
Molecular size of markers is indicated in kDa. Arrows indicate
bands that reacted with anti-RAS2 antiserum on Western blots.
with the same preparations of reagents and repeated at least
twice. Mn2" activity and maximum RAS activation varied by
less than 50% between experiments, and duplicate data
points within an experiment varied by less than 20%. Gua-
nine nucleotide binding was measured using a nitrocellulose
filter binding assay. Protein assays were performed by the
method of Bradford (2) with reagents from BioRad Labora-
tories (Richmond, Calif.).
CYRI
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FIG. 1. Scheme for construction of the plasmid pADH-CYRl.
This plasmid contains the entire open reading frame for the yeast
adenylate cyclase gene expressed from the yeast alcohol dehydro-
genase promoter. See Materials and Methods for details.
RESULTS
Assay for RAS using membranes from cells which overex-
press adenylate cyclase. Our present assays for RAS protein
stimulation of adenylate cyclase differ from our previous
assays in several significant respects. First, we use RAS2
protein extracted from an E. coli expression system intended
to express the intact RAS2 protein. Previous studies utilized
mainly an N-terminal fusion protein called f-RAS2 (3).
Second, our source of yeast adenylate cyclase derives from
membranes of yeast cells which greatly overexpress a cloned
adenylate cyclase gene. As a consequence, the current assay
has greater sensitivity. Thus, third, we have been able to
omit an ATP-regenerating system. Fourth, we have per-
formed guanine nucleotide exchange experiments with
RAS2 in the presence of EDTA, since we have observed that
nucleotide exchange is quite slow in the presence of free
Mg22 ions, and we monitored results with radiolabeled
nucleotides.
The RAS2 proteins used in these studies were purified
from an E. coli expression system which was previously
described. Sodium dodecyl sulfate-polyacrylamide gels of
the purified RAS2 and RAS2Val-19 proteins shown in Fig. 2
indicate that about 90% of the protein in this preparation is in
a band of 37 kilodaltons (kDa), somewhat smaller than the
42-kDa protein predicted from the nucleotide sequence of
RAS2. Indeed, Western blot analysis of the purified protein
with an anti-RAS2 antiserum revealed two bands, one at 42
kDa and another at 37 kDa (data not shown), suggesting that
VOL. 7, 1987
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FIG. 3. Response of yeast adenylate cyclase to RAS2 proteins
and guanine nucleotides (with accelerated exchange). (A) Effect of
wild-type protein. Guanine nucleotide exchange reactions were
monitored as follows. A 140-,ug sample of RAS2 was mixed with 10
,uCi of [3H]GDP, the "tracer" nucleotide, at 7 Ci/mmol in a total
volume of 100 p.1 of buffer G (20 mM Tris hydrochloride buffer, pH
7.5, 20 mM NaCl, 5 mM ,B-mercaptoethanol, 3 mM MgC92) supple-
mented with 7.5 mM EDTA and then incubated for 30 min at 37°C.
A sample of 1.0 ,u1 was removed, and the [3H]GDP bound to RAS2
was measured by binding to nitrocellulose filters. This value (18,300
cpm) was used as the 100% point. Next, 15 pI. of the above reaction
mixture was incubated with 15,000 pmol of the indicated "ex-
change" nucleotide in a volume of 30 p. for 60 min at 37°C and then
transferred to 0°C. A portion (2 RIl) of this mixture was removed, and
the [3H]GDP remaining bound to RAS2 was determined by filter
binding. This determined the extent of nucleotide exchange or
replacement (amounts of original nucleotide retained: with GTP
added, 0.8%; with GDP, 7.7%; with GDP-PS, 5.5%). The remainder
of the mixture was added to adenylate cyclase assays as follows.
Samples ranging from 0.5 to 10.0 p.1 were mixed with equal volumes
of 15 mM MgCl2 to give an excess of MgCl2 over EDTA. Next, the
samples were diluted to 20 p.1 of buffer G containing the indicated
guanine nucleotide, such that the final concentration of the nucleo-
tide was 250 p.M. Ten-microgram samples of membranes from rasl-
ras2- pADH-CYRI yeast strains (see Materials and Methods) were
added in a volume of 30 p.1, and the samples were incubated for 15
min at 0°C. Next, 50 p.1 of assay mix was added to the following final
concentrations: 20 mM MES [2-(N-morpholino)ethanesulfonic acid;
pH 6.2], 1 mM P-mercaptoethanol, 2.5 mM MgCl2 (or, where
indicated, 2.5 mM MnCI2), 0.5 mM cyclic AMP, 1 mM ATP, and 20
p.Ci of [a-32P]ATP (810 Ci/mmol) to a specific activity of 100 to 300
cpm/pmol. Reactions were stopped, and cyclic AMP was measured.
(B) Effects of RAS2val-19 protein. This experiment was performed as
described for panel A with the following modifications: RAS2Val-l9
was used instead of RAS2, 10 p.Ci of [a-32P]GTP was used instead of
[3H]GDP as the "tracer" nucleotide, the concentration of EDTA
the 37-kDa form of the RAS2 is a degradation product.
Amino-terminal sequence analysis indicated that the RAS2
protein began with the second amino acid predicted from the
DNA sequence (24). Thus the 37-kDa product may lack up to
50 amino acids from the carboxyl terminus, including the
cysteine residue(s) likely to be essential for posttranslational
modifications and membrane targeting of Ras proteins in
vivo (45). In Coomassie blue-stained gels, the percentage of
the 42-kDa band to the total RAS2 protein varied from less
than the 10% shown in Fig. 2 to more than 50% in other
preparations. However, all preparations were equally potent
in binding guanine nucleotides and in activating adenylate
cyclase. Apparently, modifications dependent upon an intact
C terminus are not required for RAS2 function in vitro, as
discussed by Powers et al. (25). Under saturating gua-
nine nucleotide exchange conditions, 1 pmol of RAS2 or
RAS2Val-l9 bound 0.5 to 1.0 pmol of GDP (data not shown).
Our current assay system uses membranes from rasl-
ras2- cells which express greatly elevated levels of adenyl-
ate cyclase. To create such cells, we expressed the cloned
yeast adenylate cyclase gene, CYR] (17), using the powerful
yeast alcohol dehydrogenase promoter (1) and a high-copy-
number plasmid, pADH-CYRJ (Fig. 1). This plasmid is
capable of suppressing the lethality which otherwise results
from loss of both RAS genes (data not shown) (19, 40).
Membranes from the resulting rasl- ras2- pADH-CYRI-
bearing strain contain approximately 20-fold higher levels of
adenylate cyclase activity than wild-type strains when as-
sayed with Mn2" as the divalent cation. The Mn2+-
dependent adenylate cyclase activity is not dependent on
RAS proteins (3, 6, 42).
The adenylate cyclase expressed in abundance in the
rasl- ras2- pADH-CYRI strain is fully RAS responsive. In
the absence of added RAS2 protein, we observed low
Mg2+-dependent adenylate cyclase activity in membranes
prepared from these strains. However (Fig. 3), activity could
be stimulated 20- to 50-fold by purified RAS2 protein in the
presence of both Mg2' and GTP. As in previous experiments
(3), stimulation was saturable, and, at the maximal level of
stimulation, the Mg2+-RAS2-GTP-stimulated activity was
about equal to the Mn2+-stimulated activity. The maximum
level of stimulation by RAS2 protein was 20- to 50-fold
higher than the maximum previously observed in rasl-
ras2- membranes. These experiments suggest that if RAS
proteins act on adenylate cyclase through an intermediate
protein, this intermediate protein is not present in limiting
amounts in the pADH-CYRI-bearing strain.
In most of the assays presented below, we monitored the
extent of guanine nucleotide binding to RAS2 protein. To do
this, we first bound a small amount of a radioactive "tracer"
nucleotide to RAS2 protein. We then incubated the protein
with the unlabeled nucleotide we wished to bind. The extent
to which the tracer was displaced was determined by a
nitrocellulose filter binding assay. As our work progressed it
became clear that RAS2 protein purified from E. coli must
come already bound with a guanine nucleotide, and that
guanine nucleotide binding is actually an exchange reaction
was 25 mM during guanine nucleotide exchange, and the
concentration of MgCl2 used to chelate the additional EDTA was 40
mM. Also, the concentration of GDP-PS was increased to 1 mM.
These changes were required to maximize exchange of the
[a-32P]GTP. The 100% point in this experiment corresponds to 51,200
cpm. Amounts of original nucleotide retained: with GTP added, 13%;
with GDP-PS, 5.5%.
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ACTIVATION OF YEAST RAS PROTEINS 2131
TABLE 1. Guanine nucleotide exchange in presence of MgCI2a
Exchange Labeled tracer % Label retained
nucleotide nucleotide RAS2 RAS2val-19
None [3H]GDP 100 100
GDP [3H]GDP 57 78
GTP [3H]GDP 59 81
Gpp(NH)p [3H]GDP 56 78
GDP-PS [3H]GDP 54 84
None [32P]GTP 100 100
GDP [32P]GTP 73 83
GTP [32P]GTP 70 83
Gpp(NH)p [32P]GTP 76 89
GDP-,BS [32P]GTP 72 88
a RAS proteins were preincubated for 60 min with 1 F.M either [ax-32P]GTP
(60,000 cpm/pmol) or [3H]GDP (3,000 cpm/pmol) in the presence of buffer G
(20 mM Tris hydrochloride buffer, pH 7.5, 20 mM NaCl, 5 mM 3-mer-
captoethanol, 3 mM MgCl2). RAS2 (1.9 pLg) or RAS2v`ls (5.2 p.g) was
subsequently incubated with 50 F.M of the indicated exchange nucleotides.
Incubations (50 p.l) were for 30 min at 37°C in the presence of buffer G. The
samples were then filtered through nitrocellulose filters. The value of 100%
label retained represents the following absolute values: 24.3 pmol of GDP-
bound RAS2v`ls, 23.9 pmol of GDP-bound RAS2, 14.5 pmol of GTP-bound
RAS2vaJ-l9, and 14.8 pmol of GTP-bound RAS2.
which occurs slowly in the presence of free magnesium ions
(Table 1). In the presence of EDTA, an Mg2+ ion chelator,
nucleotide exchange was greatly accelerated (see legend to
Fig. 3). The slow exchange in the presence of free Mg2+ was
exploited in one experiment (see Fig. 4).
Guanine nucleotide dependence of RAS2 proteins. We
measured the ability of wild-type RAS2 and RAS2Val-19
proteins to stimulate the Mg2+-dependent adenylate cyclase
activity when bound to various guanine nucleotides. Ade-
nylate cyclase was greatly stimulated by the addition of
RAS2 or RAS2Val-l9 proteins bound to GTP (Fig. 3). Satura-
tion of the Mg2'-dependent adenylate cyclase activity was
achieved at about 5 ,ug of either RAS2-GTP or RAS2va1-19-
GTP. As we have observed previously (3), RAS2 protein
bound to GDP was able to activate adenylate cyclase,
although only one fourth as well as protein bound to GTP
(Fig. 3A). One possible explanation for this is that RAS2
bound to GDP is indeed a weak stimulator of adenylate
cyclase. Another explanation is that, due to an ubiquitous
dinucleotide kinase in cell membranes (20), the activity seen
with RAS2 bound to GDP results from the conversion of free
GDP to GTP followed by nucleotide exchange. Support for
the latter explanation comes from experiments with the
nucleotide GDP-PS [guanosine-5'-O-(2-thiodiphosphate)I,
which cannot be directly converted to GTP. Very little
stimulation of adenylate cyclase was observed after the
addition of up to 7 p.g of RAS2 or 16 ,ug of RAS2val-19 protein
bound to GDP-PS (Fig. 3). The inactive RAS2 proteins
bound to GDP-P3S could activate adenylate cyclase after the
readdition of GTP, indicating that the failure of RAS2-GDP-
PS complexes to stimulate adenylate cyclase was not due to
denaturation of the RAS2 proteins (data not shown). In
experiments in which RAS2 was compared directly with
RAS2Val-l9, both activated adenylate cyclase with identical
dose-response curves when in their GTP-bound state (data
not shown). These experiments suggest that RAS2 and
RAS2Val-l9 proteins in their GTP-bound form are potent
activators of yeast adenylate cyclase, whereas these proteins
in their GDP-bound form may be virtually inactive. The
difference in potency of the two forms may be as great as
20-fold. Recently, De Vendittis et al. reported similar results
using wild-type yeast RAS2 (11).
RAS2 bound with GDP-PS does not inhibit stimulation of
adenylate cyclase by RAS2 bound with Gpp(NH)p. The ob-
servations that nucleotide exchange occurs slowly in the
presence of Mg2+ (Table 1) allowed us to test the competi-
tion between active and inactive forms of RAS2 (Fig. 4). To
do this we bound wild-type RAS2 with Gpp(NH)p
[guanosine-5'(3,By-imino)triphosphate], a nonhydrolyzable
GTP analog. Under conditions in which essentially complete
nucleotide exchange could be demonstrated, Gpp(NH)p-
bound RAS2 activated adenylate cyclase as well as GTP-
bound RAS2 (not shown). We bound another sample of
RAS2 to GDP-,BS. Both nucleotides were bound to RAS2 in
the presence of EDTA to accelerate exchange, and then the
proteins were dialyzed to remove unbound nucleotide and
EDTA. Adenylate cyclase assays were then performed
without exogenously added nucleotide. As expected,
Gpp(NH)p-bound RAS2 activated adenylate cyclase, and
GDP-,S-bound RAS2 did not activate adenylate cyclase. In
competition assays the total amount of RAS2 was main-
tained at a saturating level, while the ratios of active to
inactive RAS2 were varied over a 10-fold range. Essentially
no inhibition was seen which could be attributed to
competiton between the active and inactive forms of RAS2,
although noncompetitive inhibition was observed in some,
but not all experiments. Thus we conclude that the inactive
form of RAS2 does not compete with the active form of
RAS2 for the stimulation of adenylate cyclase. Essentially
identical results were obtained using GDP-,S-bound RAS2
and GTP-bound RAS2val-19 (data not shown).
FIG. 4. Competition between Gpp(NH)p-bound RAS2 and GDP-
PS-bound RAS2. Wild-type RAS2 protein was treated with either
GDP-PS or Gpp(NH)p in the presence of 25 mM EDTA in buffer G
and then dialyzed against buffer G containing 50% glycerol to
remove unbound nucleotides. [3H]GDP tracer binding indicated that
95% exchange had occurred for GDP-PS and 70% exchange had
occurred for Gpp(NH)p. When re-exchanged with GTP, each pro-
tein could activate adenylate cyclase as well as untreated protein
(not shown). (0) Gpp(NH)p-treated RAS2 alone; (0) GDP-PS-
treated RAS2; (O) Gpp(NH)p-treated RAS2 plus GDP-PS-treated
RAS2 (total RAS2 protein constant at 24 p.g). The inset shows that
RAS2 bound with GDB-PS is inactive.
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FIG. 5. Model for RAS2 activation of adenylate cyclase. See text
for details.
DISCUSSION
We have modified the system for the in vitro biochemical
assay of RAS protein function by using membranes from an
S. cerevisiae strain overexpressing the adenylate cyclase
gene. Interestingly, when overexpressed in S. cerevisiae.
adenylate cyclase was fully responsive to RAS2. Thus, if
there is an intermediate between RAS2 and adenylate cy-
clase, it is not present in limiting amounts. Another group
has concluded that S. cerevisiae RAS proteins interact
directly with adenylate cyclase, based on their report that
the yeast adenylate cyclase gene, when expressed in E. ( oli
is still activated by RAS (43). We have been unable to
confirm these results (17). Moreover, the adenylate cyclase
plasmid they used lacked regions of the gene which we know
confer RAS regulation in S. cerevisiae (unpublished data).
Further studies are required to determine whether RAS acts
directly or indirectly on adenylate cyclase.
Our guanine nucleotide activation experiments (Fig. 3 and
4) suggest that both RAS2 and RAS2val-19 activate yeast
adenylate cyclase when in their GTP-bound state. As we
previously reported, GDP-bound RAS is capable of weakly
stimulating adenylate cyclase (3). However, based on results
with the GDP analog GDP-PS (Fig. 3 and 4), we believe that
this weak stimulation results from rebinding of GTP regen-
erated from GDP. RAS2 bound to GDP-PS is at most 10% as
active as RAS2 bound to GTP. Although we cannot com-
pletely exclude that RAS2 bound to the GDP analog assumes
a nonphysiological conformation, RAS2 in this form can be
reactivated by the addition of GTP.
Our competition data suggest that the active GTP-bound
form of RAS2 binds its effector, while the inactive. GDP-
bound form does not bind or does so less effectively. A
simple consequence of the competition experiment is that
the cellular signal due to RAS2 will be a function of the
presence of the active form only, and not a function of the
ratio of active to inactive forms. This is consistent with the
genetic data in S. cerevisiae that the RAS2Val-l9 phenotype is
dominant even in the presence of wild-type RAS2 (19).
Taken together, our studies of RAS2 protein-adenylate cy-
clase interactions supports the model, shown in Fig. 5, in
which RAS2 shuttles between a conformationally active
GTP-bound state and an inactive GDP-bound state. The
amount of time spent in the active state may be determined
by the intrinsic GTP hydrolysis rate as well as by other
proteins which may interact with RAS2. Only the active
conformation binds its effector.
The mammalian H-ras protein is capable of functioning in
the S. cerevisiae system both in vivo and in vitro (3, 10, 18),
so it is tempting to extend our conclusions to the mammalian
cell. Some oncogenic forms of mammalian ras genes encode
proteins that, like the yeast RAS2Val-l9 proteins, have re-
duced GTPase activity (14, 21, 35). It has been proposed that
transformation by these proteins results from a defective
turn-off mechanism. Our experiments support this model,
since they suggest that the GDP-bound form of RAS2 is
virtually inactive. Moreover, mammalian cells can be trans-
formed by overexpression of wild-type ras genes (7). Our
competition data suggest that transformation in this case
might result from an increase in the total amount of GTP-
bound Ras, even though the ratio of the GTP-bound Ras to
the GDP-bound form might not change.
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